Chief Financial Officer
Our commitment to transforming the lives of people with rare diseases drives what we do.
Former CFO of public and private companies with 25+ years of experience in the life science industry. Career highlights: •Provention: $64 million initial public offering and several follow-on offerings that generated proceeds of $250 million; negotiated agreements with MacroGenics and Amgen, resulting in the addition of three products to Provention’s pipeline, including a Phase 3 program for the interception of type-one diabetes; grew company from 5 to 85 employees. •Insmed: Raised more than $400 million at Insmed through equity offerings; grew company from 36 to 160 employees. •VaxInnate: secured $200 million in U.S. government funding in addition to raising over $40 million in venture capital •Valera: led initial public offering and eventual sale to Indevus (now Endo)